Schneider J, Brichard V, Boon T, Meyer zum Büschenfelde K H, Wölfel T
I Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, Mainz, Germany.
Int J Cancer. 1998 Jan 30;75(3):451-8. doi: 10.1002/(sici)1097-0215(19980130)75:3<451::aid-ijc20>3.0.co;2-a.
From the peripheral blood lymphocytes (PBLs) of melanoma patient SK29(AV) we have previously isolated 2 independent cytolytic T lymphocyte (CTL) clones (CTL7/147 and CTL13/211), which lysed autologous tumor cells in association with HLA-B45.1. As demonstrated here, both CTL clones were directed against melanocyte differentiation antigen Melan-A/MART-1, which also was recognized by HLA-A2.1-restricted CTLs from the same patient. By generating and transfecting 3'-deletion mutants of Melan-A/MART-1 cDNA, we localized its peptide-coding regions. The HLA-B45.1-presented peptides were derived from a hydrophobic region of the protein and largely overlapped the peptides recognized by CTLs from the same patient in association with HLA-A2.1. We determined the fine specificity of these CTL clones with synthetic peptides. CTL clone CTL7/147 recognized the 11-mer peptide AEEAAGIGILT (residues 24-34) at the lowest concentrations. The absence of threonine-34 abrogated the recognition by CTL7/147. The truncated peptide AEEAAGIGIL (residues 24-33) proved to be the optimal synthetic peptide for sensitization against lysis by CTL13/211. This indicated that C-terminal threonine-34 was not involved in binding to HLA-B45.1 but, rather, was part of the epitope for CTL7/147. HLA-B45.1-associated peptides of Melan-A/MART-1 were regularly processed and presented by other melanomas and other cell types. Three of 4 independent HLA-A2.1-restricted SK29-CTL clones recognized the 10-mer peptide EAAGIGILTV (residues 26-35) at 10- to 100-fold lower concentrations than the nonamer AAGIGILTV (residues 27-35), previously described as the common immunodominant peptide antigen for all known anti-Melan-A/MART-1 CTLs restricted by HLA-A2.1. Different melanoma peptide antigens currently are applied in therapeutic vaccination studies. Our findings emphasize that restricting to peptides of minimal length might exclude relevant T-cell epitopes.
我们之前从黑色素瘤患者SK29(AV)的外周血淋巴细胞(PBLs)中分离出2个独立的细胞毒性T淋巴细胞(CTL)克隆(CTL7/147和CTL13/211),它们与HLA - B45.1共同作用裂解自体肿瘤细胞。如本文所示,这两个CTL克隆均针对黑素细胞分化抗原Melan - A/MART - 1,来自同一患者的HLA - A2.1限制性CTL也能识别该抗原。通过构建和转染Melan - A/MART - 1 cDNA的3' - 缺失突变体,我们定位了其肽编码区。HLA - B45.1呈递的肽源自该蛋白的一个疏水区,并且与来自同一患者的与HLA - A2.1相关的CTL所识别的肽在很大程度上重叠。我们用合成肽确定了这些CTL克隆的精细特异性。CTL克隆CTL7/147在最低浓度下识别11聚体肽AEEAAGIGILT(第24 - 34位氨基酸残基)。苏氨酸 - 34缺失则消除了CTL7/147的识别。截短的肽AEEAAGIGIL(第24 - 33位氨基酸残基)被证明是用于致敏以抵抗CTL13/211裂解的最佳合成肽。这表明C末端的苏氨酸 - 34不参与与HLA - B45.1的结合,而是CTL7/147表位的一部分。Melan - A/MART - 1的HLA - B45.1相关肽通常由其他黑色素瘤和其他细胞类型加工并呈递。4个独立的HLA - A2.1限制性SK29 - CTL克隆中的3个识别10聚体肽EAAGIGILTV(第26 - 35位氨基酸残基),其浓度比之前描述的作为所有已知的受HLA - A2.1限制的抗Melan - A/MART - 1 CTL的共同免疫显性肽抗原的9聚体AAGIGILTV(第27 - 35位氨基酸残基)低10至100倍。目前不同的黑色素瘤肽抗原被应用于治疗性疫苗接种研究。我们的研究结果强调,局限于最短长度的肽可能会排除相关的T细胞表位。